{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-012083","form_type":"8-K","ticker":"ROIV","cik":"0001635088","company_name":"Roivant Sciences Ltd.","filed_at":"2023-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.943253+00:00","generated_at":"2026-06-18T00:34:53.054111+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Roivant Sciences appoints Meghan FitzGerald to board and Ilan Oren as Chairman","bullets":["Meghan M. FitzGerald appointed as Class II director and member of Nominating & Governance Committee, effective March 13, 2023.","FitzGerald is a global healthcare strategist with experience at Cardinal Health, Pfizer, Sanofi, and adjunct professor at Columbia University.","Board appointed Ilan Oren as Chairman; Oren has been a director since 2014 and Co-CEO of Dexcel Pharma.","FitzGerald will receive cash and equity compensation per company's Non-Executive Director Compensation Policy; initial equity grant in April 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-012083","json":"https://secwatch.observer/filing/0001140361-23-012083.json","markdown":"https://secwatch.observer/filing/0001140361-23-012083.md","text":"https://secwatch.observer/filing/0001140361-23-012083.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123012083/0001140361-23-012083-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123012083/brhc10049884_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T00:34:53.054111+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3fea7db250","claim":"Ilan Oren was appointed as Chairman of the Board at Roivant Sciences Ltd..","evidence_excerpt":"In addition, the Board has appointed Ilan Oren as Chairman of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123012083/0001140361-23-012083-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chairman of the Board"}],"fact_type":"executive_change"},{"claim_id":"989efa66f9","claim":"Meghan M. FitzGerald was appointed as Class II Director at Roivant Sciences Ltd..","evidence_excerpt":"On March 13, 2023, the Board of Directors (the “Board”) of Roivant Sciences Ltd. (the “Company”) appointed Meghan M. FitzGerald, DrPH, to serve as a Class II director of the Company and as a member of the Nominating and Governance Committee of the Board, effective as of that date, filling a vacancy on the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123012083/0001140361-23-012083-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}